April Journal-2009.p65 - Association of Biotechnology and Pharmacy

More documents

Recommendations

Info

Current Trends in Biotechnology and Pharmacy Vol. 3 (2) April 2009. ISSN 0973-8916 Fig.1 a Cumulative % drug release of Levodopa Fig.2b Cumulative % drug release of Carbidopa Fig.1b Cumulative % drug release of Carbidopa Fig. 3a Cumulative % drug release of Levodopa Fig.2a Cumulative % drug release of Levodopa Fig. 3b Cumulative % drug release of Carbidopa InVitro Evaluation
Current Trends in Biotechnology and Pharmacy Vol. 3 (2) April 2009. ISSN 0973-8916 Table 1. Composition of levodopa and carbidopa (200mg+50mg) controlled release tablet formulations Each 400mg LDCD CR formulation contains 0.025% Brilliant blue, 0.1% Ascorbic acid, 0.625% Talc, 0.625% Aerosil. MCC: Microcrystalline cellulose, LDCD CR: Levodopa Carbidopa Controlled Release. Table: 2 Micromeritic properties of drugs (levodopa and carbidopa) Jagan et al
Page 2 and 3:
Current Trends in Biotechnology and
Page 4 and 5:
Association of Biotechnology and Ph
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50:
Page 54 and 55: Current Trends in Biotechnology and
show all

April Journal-2009.p65 - Association of Biotechnology and Pharmacy

Create successful ePaper yourself

Delete template?

Save as template?